West Pharmaceutical Services (WST) P/E ratio
West Pharmaceutical Services (WST) trades at 46.5× its earnings per share over the last twelve months. At the end of fiscal 2025 (December 31, 2025) its P/E ratio was 40.5×. That is 17.2% lower than the 49.0× of fiscal 2024. Figures as of 18 Nov 2026, 06:37 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/E ratio today
- 46.5×
- P/E ratio, fiscal 2025
- 40.5×
- Change on fiscal 2024
- −17.2%
- Highest on record
- 62.0×fiscal 2020
- Lowest on record
- 15.1×fiscal 2008
- Fiscal years on record
- 182008–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
West Pharmaceutical Services P/E ratio, in more detail
Today's figure is 14.7% above the fiscal 2025 year-end.
Across the 18 fiscal year-ends on record (2008–2025), the highest was 62.0× in fiscal 2020 and the lowest 15.1× in fiscal 2008. Today's P/E ratio is higher than at 72% of the 18 fiscal year-ends on record; their median is 38.1×.
P/E ratio at each fiscal year-end
The last point is today's figure; the others are fiscal year-ends.
West Pharmaceutical Services P/E ratio, year by year
| Fiscal year | P/E ratio | Change | Year ended | Share price at year-end | Diluted EPS |
|---|---|---|---|---|---|
| Today | 46.5× | — | $414.12 | — | |
| 2025 | 40.5× | 17.2% down | $275.14 | $6.79 | |
| 2024 | 49.0× | 9.6% up | $327.56 | $6.69 | |
| 2023 | 44.7× | 46.8% up | $352.12 | $7.88 | |
| 2022 | 30.4× | 43.7% down | $235.35 | $7.73 | |
| 2021 | 54.1× | 12.7% down | $469.01 | $8.67 | |
| 2020 | 62.0× | 32.4% up | $283.31 | $4.57 | |
| 2019 | 46.8× | 30.9% up | $150.33 | $3.21 | |
| 2018 | 35.8× | 27.8% down | $98.03 | $2.74 | |
| 2017 | 49.6× | 11.6% up | $98.67 | $1.99 | |
| 2016 | 44.4× | 4.1% down | $84.83 | $1.91 | |
| 2015 | 46.3× | 52.3% up | $60.22 | $1.30 | |
| 2014 | 30.4× | 2.6% down | $53.24 | $1.75 | |
| 2013 | 31.2× | 31.3% up | $49.06 | $1.57 | |
| 2012 | 23.8× | 35.5% up | $27.38 | $1.15 | |
| 2011 | 17.6× | 19.4% down | $18.98 | $1.08 | |
| 2010 | 21.8× | 17.9% up | $20.60 | $0.95 | |
| 2009 | 18.5× | 22.4% up | $19.60 | $1.06 | |
| 2008 | 15.1× | — | $18.89 | $1.25 |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.
How to read it
It is the number of years of current profit the price pays for — a high figure means investors expect growth, and it is best judged against the company's own history.
P/E ratio at health care companies of similar size
| Company | P/E ratio |
|---|---|
| Labcorp Holdings LH | 30.2× |
| DexCom DXCM | 32.3× |
| Koninklijke Philips PHG | 26.0× |
| West Pharmaceutical Services WST | 46.5× |
| Quest Diagnostics DGX | 25.5× |
Price over the last twelve months' earnings per share, as the market data feed reports it.
West Pharmaceutical Services, figure by figure
- West Pharmaceutical Services market cap
- West Pharmaceutical Services revenue
- West Pharmaceutical Services earnings
- West Pharmaceutical Services earnings per share (EPS)
- West Pharmaceutical Services P/S ratio
- West Pharmaceutical Services P/B ratio
- West Pharmaceutical Services free cash flow
- West Pharmaceutical Services operating margin
- West Pharmaceutical Services dividend
- West Pharmaceutical Services shares outstanding
- West Pharmaceutical Services total debt
- West Pharmaceutical Services cash on hand
- West Pharmaceutical Services total assets
- West Pharmaceutical Services return on equity (ROE)
- West Pharmaceutical Services return on invested capital (ROIC)
West Pharmaceutical Services (WST) overview: price, valuation and scorecardAll health care companies by market value
West Pharmaceutical Services P/E ratio: questions and answers
What is West Pharmaceutical Services's P/E ratio?
West Pharmaceutical Services (WST) trades at 46.5× its earnings per share over the last twelve months. At the end of fiscal 2025 (December 31, 2025) its P/E ratio was 40.5×. That is 17.2% lower than the 49.0× of fiscal 2024.
Is West Pharmaceutical Services's P/E ratio high or low compared with its own history?
Today's P/E ratio is higher than at 72% of the 18 fiscal year-ends on record; their median is 38.1×.
What are the highest and lowest P/E ratio figures on record for West Pharmaceutical Services?
Across the 18 fiscal year-ends on record (2008–2025), the highest was 62.0× in fiscal 2020 and the lowest 15.1× in fiscal 2008.
How is West Pharmaceutical Services's P/E ratio calculated?
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/E ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “West Pharmaceutical Services (WST) P/E ratio”, data as of 18 November 2026. https://funkfolio.com/stock/WST/pe-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.